CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint

Data Compilation
#PharmaFlow

Pipeline Prospector July 2025: Merck to acquire Verona for US$ 10 bn; FDA okays Regeneron’s blood cancer med

Stock Recap
#PipelineProspector

Gemzar, Gemcitabine Hydrochloride

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

99 API Suppliers, 29 USDMF, 26 CEP/COS, 12 JDMF, 9 EU WC, 30 KDMF, 18 NDC API, 44 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

329 Drugs in Development

329 Drugs in Development

INTERMEDIATES

19 Intermediate Suppliers

19 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

244 FDF Dossiers, 91 FDA Orange Book, 89 Europe, 4 Canada, 4 Australia, 17 South Africa, 39 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 200MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;INTRAVENOUS - EQ 1200MG BASE/120ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1300MG BASE/130ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1400MG BASE/140ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1500MG BASE/150ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1600MG BASE/160ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1700MG BASE/170ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1800MG BASE/180ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 1900MG BASE/190ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 2000MG BASE/200ML (EQ 10MG BASE/ML), SOLUTION;INTRAVENOUS - EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 13 SPI Pharma, 1 Gangwal Healthcare, 1 Pfanstiehl, 1 Actylis, 1 BASF, 2 Gangwal Chemicals, 1 Ingredion Pharma Solutions, 1 Kerry, 2 Microlex e.U, 1 Pluviaendo, 3 Roquette, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

17 Fillers, Diluents & Binders, 12 Chewable & Orodispersible Aids, 10 Taste Masking, 10 Direct Compression, 7 Disintegrants & Superdisintegrants, 5 Parenteral, 3 Co-Processed Excipients, 3 Granulation, 1 Solubilizers, 1 Thickeners and Stabilizers

DIGITAL CONTENT

2 Data Compilation #PharmaFlow, 114 News #PharmaBuzz

GLOBAL SALES INFORMATION

10 US Medicaid Prescriptions, 69 Regulatory FDF Prices, 2 Annual Reports

MARKET PLACE

17 APIs, 9 FDF Dossiers, 2 Intermediates

PATENTS & EXCLUSIVITIES

10 US Patents

10 US Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 3 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Certificate Holder	Certificate No.	Substance	Issue Date	Status	Type	End Date	Substance No.
29/07/2025	Dr. Reddy's Laboratories	India	DR. REDDY'S LABORATORIES LIMITED Hyderabad IN	R1-CEP 2007-075 - Rev 06	Gemcitabine hydrochloride	2021-06-18	Valid	Chemical		2306
29/07/2025	Arch Pharmalabs	India	ARCH PHARMALABS LIMITED Mumbai IN	R0-CEP 2011-023 - Rev 01	Gemcitabine hydrochloride, Product code: GAI	2014-04-25	Withdrawn by EDQM Failure to CEP procedure	Chemical	2020-03-13	2306

Gemzar, Gemcitabine Hydrochloride

Gemzar, Gemcitabine Hydrochloride

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

99 API Suppliers

29 USDMF

26 CEP/COS

12 JDMF

9 EU WC

30 KDMF

18 NDC API

44 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

329 Drugs in Development

INTERMEDIATES

19 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

244 FDF Dossiers

91 FDA Orange Book

89 Europe

4 Canada

4 Australia

17 South Africa

39 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 200MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SOLUTION;INTRAVENOUS - EQ 1200MG BASE/120ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1300MG BASE/130ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1400MG BASE/140ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1500MG BASE/150ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1600MG BASE/160ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1700MG BASE/170ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1800MG BASE/180ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 1900MG BASE/190ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 2000MG BASE/200ML (EQ 10MG BASE/ML)

SOLUTION;INTRAVENOUS - EQ 2200MG BASE/220ML (EQ 10MG BASE/ML)

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc

13 SPI Pharma

1 Gangwal Healthcare

1 Pfanstiehl

1 Actylis

1 BASF

2 Gangwal Chemicals

1 Ingredion Pharma Solutions

1 Kerry

2 Microlex e.U

1 Pluviaendo

3 Roquette

1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

1 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

17 Fillers, Diluents & Binders

12 Chewable & Orodispersible Aids

10 Taste Masking

10 Direct Compression

7 Disintegrants & Superdisintegrants

5 Parenteral

3 Co-Processed Excipients

3 Granulation

1 Solubilizers

1 Thickeners and Stabilizers

DIGITAL CONTENT

2 Data Compilation #PharmaFlow

114 News #PharmaBuzz

GLOBAL SALES INFORMATION

10 US Medicaid Prescriptions

69 Regulatory FDF Prices

2 Annual Reports

MARKET PLACE

17 APIs

9 FDF Dossiers

2 Intermediates

PATENTS & EXCLUSIVITIES

INJECTABLE;INJECTION - EQ 1GM BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - EQ 200MG BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons